Compare · LLY vs LXRX
LLY vs LXRX
Side-by-side comparison of Eli Lilly and Company (LLY) and Lexicon Pharmaceuticals Inc. (LXRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and LXRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.08T, about 1043.6x LXRX ($1.03B).
- Over the past year, LLY is up 50.5% and LXRX is up 91.0% - LXRX leads by 40.5 points.
- LLY has hit the wire 5 times in the past 4 weeks while LXRX has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 5 for LXRX).
- Company
- Eli Lilly and Company
- Lexicon Pharmaceuticals Inc.
- Price
- $1146.38-2.73%
- $2.34-2.09%
- Market cap
- $1.08T
- $1.03B
- 1M return
- +3.08%
- +15.27%
- 1Y return
- +50.51%
- +91.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 5
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Latest LLY
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Three Biotechs Deliver Catalysts to Watch
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend
Latest LXRX
- Director Swain Judith L converted options into 89,312 shares, increasing direct ownership by 105% to 174,486 units (SEC Form 4)
- Director Sullivan Diane E. converted options into 89,312 shares, increasing direct ownership by 243% to 126,122 units (SEC Form 4)
- Director Sobecki Christopher J converted options into 89,312 shares, increasing direct ownership by 44% to 293,177 units (SEC Form 4)
- Director Cheung Ivan converted options into 89,312 shares (SEC Form 4)
- Director Amouyal Philippe converted options into 89,312 shares, increasing direct ownership by 31% to 374,486 units (SEC Form 4)
- Director Barker Sam L converted options into 89,312 shares, increasing direct ownership by 72% to 213,771 units (SEC Form 4)
- Director Debbane Raymond converted options into 89,312 shares, increasing direct ownership by 5% to 1,995,498 units (SEC Form 4)
- Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
- Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
- Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference